Aquaporin-4 Immunoglobulin G-seropositive Neuromyelitis Optica Spectrum Disorder MRI Characteristics: Data Analysis from the International Real-World PAMRINO Study Cohort

Background Patients with neuromyelitis optica spectrum disorder (NMOSD) are often seropositive for antibodies against aquaporin-4 (AQP4). The importance of MRI monitoring in this disease requires evaluation. Purpose To profile MRI features from a large international cohort with AQP4 immunoglobulin G (IgG)-seropositive NMOSD (from the Parallel MRI in NMOSD [PAMRINO] study) and to evaluate and confirm existing knowledge regarding the incidence, location, and longitudinal development of characteristic lesions in the central nervous system associated with AQP4-IgG-seropositive NMOSD. Materials and Methods In this retrospective study (from August 2016 to January 2019), MRI and clinical data were collected from 17 NMOSD expert sites in 11 countries across four continents. Clinical features and lesions identified at cross-sectional and longitudinal MRI were assessed. No formal statistical tests were used to compare observations; however, means, SDs, and 95% CIs are reported when evaluating lesion frequencies. Results Available T1-weighted and T2-weighted MRI scans in patients with AQP4-IgG-seropositive NMOSD ( = 525) were read. Among the 525 patients, 320 underwent cerebral MRI examinations with T2-weighted hyperintense cerebral (264 of 320; 82.5%), cerebellar (44 of 320; 13.8%), and brainstem (158 of 321 [49.2%], including one lesion observed at cervical spinal cord [SC] MRI) lesions. Lesions in the optic nerves, analyzed from 152 MRI examinations, were mainly found in the central (81 of 92; 88%) and posterior (79 of 92; 86%) sections (bilaterally in 39 of 92; 42%). Longitudinally extensive transverse myelitis was the predominant SC lesion pattern (upper compartment from 322 MRI examinations, 133 of 210 [63.3%]; and lower compartment from 301 MRI examinations, 149 of 212 [70.3%]). However, nonlongitudinal extensive transverse myelitis lesions were also observed frequently (105 of 210; 50.0%) in the cervical SC. Clinical data ( = 349; mean age, 44 years ± 14 [SD]; 202 female patients) and acute lesions at contrast-enhanced (CE) MRI ( = 58, performed within 30 days of the last attack) were evaluated. CE lesions were detected in the cerebrum (eight of 13; 62%), optic nerves (14 of 19; 74%), or chiasm (three of four; 75%) within 15 days of any relapse. In the upper SC (29 of 44; 66%), CE lesions were frequently observed up to 20 days after a clinical myelitis event. Conclusion A high incidence of abnormal brain MRI examinations and nonlongitudinal extensive SC lesions was found in patients in PAMRINO with AQP4-IgG-seropositive NMOSD. © RSNA, 2024

References

Chien C, Scheel M, Schmitz-Hubsch T, Borisow N, Ruprecht K, Bellmann-Strobl J . Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity. Mult Scler. 2018; 25(14):1926-1936. DOI: 10.1177/1352458518815596. View

Jurynczyk M, Tackley G, Kong Y, Geraldes R, Matthews L, Woodhall M . Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry. 2016; 88(2):132-136. DOI: 10.1136/jnnp-2016-314005. View

Fang W, Zheng Y, Yang F, Cai M, Shen C, Liu Z . Short segment myelitis as the initial and only manifestation of aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord. 2020; 13:1756286419898594. PMC: 6971969. DOI: 10.1177/1756286419898594. View

Yonezu T, Ito S, Mori M, Ogawa Y, Makino T, Uzawa A . "Bright spotty lesions" on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Scler. 2013; 20(3):331-7. DOI: 10.1177/1352458513495581. View

Carnero Contentti E, Lopez P, Tkachuk V, Vrech C, Zarate M, Correale J . Frequency of new asymptomatic MRI lesions during attacks and follow-up of patients with NMOSD in a real-world setting. Mult Scler. 2023; 29(10):1240-1249. DOI: 10.1177/13524585231187120. View

Lerch M, Schanda K, Lafon E, Wurzner R, Mariotto S, Dinoto A . More Efficient Complement Activation by Anti-Aquaporin-4 Compared With Anti-Myelin Oligodendrocyte Glycoprotein Antibodies. Neurol Neuroimmunol Neuroinflamm. 2022; 10(1). PMC: 9682624. DOI: 10.1212/NXI.0000000000200059. View

Becker M, Masterson K, Delavelle J, Viallon M, Vargas M, Becker C . Imaging of the optic nerve. Eur J Radiol. 2010; 74(2):299-313. DOI: 10.1016/j.ejrad.2009.09.029. View

Flanagan E, Weinshenker B, Krecke K, Lennon V, Lucchinetti C, McKeon A . Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol. 2014; 72(1):81-7. PMC: 4552048. DOI: 10.1001/jamaneurol.2014.2137. View

Finke C, Heine J, Pache F, Lacheta A, Borisow N, Kuchling J . Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD. Neurol Neuroimmunol Neuroinflamm. 2016; 3(3):e229. PMC: 4841641. DOI: 10.1212/NXI.0000000000000229. View

10.

Cortese R, Carrasco F, Tur C, Bianchi A, Brownlee W, De Angelis F . Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging. Neurology. 2022; 100(3):e308-e323. PMC: 9869760. DOI: 10.1212/WNL.0000000000201465. View

11.

Xu Y, Ren Y, Li X, Xu W, Wang X, Duan Y . Persistently Gadolinium-Enhancing Lesion Is a Predictor of Poor Prognosis in NMOSD Attack: a Clinical Trial. Neurotherapeutics. 2021; 18(2):868-877. PMC: 8423888. DOI: 10.1007/s13311-020-00973-9. View

12.

Harris P, Taylor R, Minor B, Elliott V, Fernandez M, ONeal L . The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019; 95:103208. PMC: 7254481. DOI: 10.1016/j.jbi.2019.103208. View

13.

Sperber P, Brandt A, Zimmermann H, Bahr L, Chien C, Rekers S . Berlin Registry of Neuroimmunological entities (BERLimmun): protocol of a prospective observational study. BMC Neurol. 2022; 22(1):479. PMC: 9749207. DOI: 10.1186/s12883-022-02986-7. View

14.

Shahriari M, Sotirchos E, Newsome S, Yousem D . MOGAD: How It Differs From and Resembles Other Neuroinflammatory Disorders. AJR Am J Roentgenol. 2020; 216(4):1031-1039. DOI: 10.2214/AJR.20.24061. View

15.

Jurynczyk M, Geraldes R, Probert F, Woodhall M, Waters P, Tackley G . Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain. 2017; 140(3):617-627. DOI: 10.1093/brain/aww350. View

16.

Szewczyk A, Papuc E, Mitosek-Szewczyk K, Wos M, Rejdak K . NMOSD-Diagnostic Dilemmas Leading towards Final Diagnosis. Brain Sci. 2022; 12(7). PMC: 9313254. DOI: 10.3390/brainsci12070885. View

17.

Cannistraro R, Badi M, Eidelman B, Dickson D, Middlebrooks E, Meschia J . CNS small vessel disease: A clinical review. Neurology. 2019; 92(24):1146-1156. PMC: 6598791. DOI: 10.1212/WNL.0000000000007654. View

18.

Jarius S, Paul F, Weinshenker B, Levy M, Kim H, Wildemann B . Neuromyelitis optica. Nat Rev Dis Primers. 2020; 6(1):85. DOI: 10.1038/s41572-020-0214-9. View

19.

Wingerchuk D, Banwell B, Bennett J, Cabre P, Carroll W, Chitnis T . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2):177-89. PMC: 4515040. DOI: 10.1212/WNL.0000000000001729. View

20.

Camera V, Holm-Mercer L, Ali A, Messina S, Horvat T, Kuker W . Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder. JAMA Netw Open. 2021; 4(12):e2137833. PMC: 8655599. DOI: 10.1001/jamanetworkopen.2021.37833. View